- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04563455
Relationship Between Grip Endurance, Disability of Upper Extremity and Quality of Life in Patients With RA
September 23, 2020 updated by: Melissa Köprülüoğlu, Izmir Katip Celebi University
Investigation of the Relationship Between Grip Endurance, Disability of Upper Extremity and Quality of Life in Patients With Rheumatoid Arthritis
The aim of this study is to investigate the relationship between grip endurance, disability of upper extremity and quality of life in patients with rheumatoid arthritis.
Study Overview
Status
Completed
Conditions
Detailed Description
Upper extremity functions affect the quality of life at different levels in patients with rheumatoid arthritis (RA).
In the current literature; it has been shown that grip endurance is associated with upper limb functions.
However, there is no study investigating the relationship between grip endurance and quality of life in patients with RA.
The purpose of this study is to investigate the relationship between grip endurance, disability of upper extremity, and quality of life in patients with RA.
Study Type
Observational
Enrollment (Actual)
23
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Izmir/ Cigli
-
Izmir, Izmir/ Cigli, Turkey
- Izmir Katip Celebi University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The population of the study consists of RA patients.
Description
Inclusion Criteria:
- RA patients were classified according to the ACR 2010 criteria.
- taking regular medication.
Exclusion Criteria:
- having a history of trauma or surgery in the upper limb.
- having neurological, cognitive, or psychiatric diseases.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Static Grip Endurance
Time Frame: Data collection will continue until December 2019. Data analysis and report preparation will be completed by September 2020.
|
Static grip endurance was evaluated by Hand Dynamometer (Lafayette Proffessional Hand Dynamometer, USA).
The maximum gripping time of 50% of the maximum grip force was recorded.
|
Data collection will continue until December 2019. Data analysis and report preparation will be completed by September 2020.
|
|
Dynamic Grip Endurance
Time Frame: Data collection will continue until December 2019. Data analysis and report preparation will be completed by September 2020.
|
Dynamic grip endurance was evaluated by Hand Dynamometer (Lafayette Proffessional Hand Dynamometer, USA).
The percentage change between the first 3 grips and the last 3 grips after 10 consecutive grips is recorded.
|
Data collection will continue until December 2019. Data analysis and report preparation will be completed by September 2020.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disability of Upper Extremity
Time Frame: Data collection will continue until December 2019. Data analysis and report preparation will be completed by September 2020.
|
This parameter was evaluated by Disability of Arm, Shoulder and Hand (DASH) questionairre.
|
Data collection will continue until December 2019. Data analysis and report preparation will be completed by September 2020.
|
|
Quality of Life Parameters
Time Frame: Data collection will continue until December 2019. Data analysis and report preparation will be completed by September 2020.
|
This parameter was evaluated by Short Form-36.
|
Data collection will continue until December 2019. Data analysis and report preparation will be completed by September 2020.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Melissa KÖPRÜLÜOĞLU, İzmir Katip Celebi University, Faculty of Health Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 1, 2019
Primary Completion (ACTUAL)
April 1, 2020
Study Completion (ACTUAL)
September 10, 2020
Study Registration Dates
First Submitted
September 23, 2020
First Submitted That Met QC Criteria
September 23, 2020
First Posted (ACTUAL)
September 24, 2020
Study Record Updates
Last Update Posted (ACTUAL)
September 24, 2020
Last Update Submitted That Met QC Criteria
September 23, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IzmirKatip Celebi University
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
Yuanyuan ZhangRecruitingRheumatoid Arthritis (RA) | Rheumatoid Arthritis-Associated Interstitial Lung Disease | Difficult-to-Treat Rheumatoid ArthritisChina
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
University Hospital, ToulouseCompletedRheumatoId ArthritisFrance
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
-
David Grant U.S. Air Force Medical CenterCompleted